Tumour treatment with anti-erbb2 antibodies
CA 2374085 C · Owner: Cohen, Robert L. · Inventors: Cohen, Robert L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method treating a human patient to or diagnosed with a tumor in which ErbB2 protein is expressed comprising the following steps performed sequentially: , (a) treating the patient with a therapeutically effective amount of an anti- ErbB2 antibody; (b) surgically removing the tumor and then (c) treating the , patient with a therapeutically effective amount of an anti-ErbB2 antibody or of a chemotherapeutic agent.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 9, 2000 and granted December 29, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 9, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 9, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.